Biggest News Aggregation in the World
📰 Recommended Phase News

Page 8 - Recommended Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Recommended Phase. Real-time updates on events, politics, business and more.

Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

- Webcast to be Held at 4:00 p.m. ET on Friday, June 4 - DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call
United States Valentina Boni Omid Hamid Sandy Coombs Sourojit Bhowmick American Society Of Clinical Oncology

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S

Share this article Share this article SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity of BBT-176 in non-small cell lung cancer (NSCLC) patients who acquired osimertinib-resistant EGFR triple mutations. BBT-176, a novel epidermal growth factor rec...
Kyonggi Do South Korea United Kingdom Republic Of Korea James Lee Biotherapeutics Inc

Catapult Therapeutics receives FDA Clearance of Investigational New Drug (IND) Application for CAP-100, an innovative first-in-class humanized anti-CCR7 antibody

/PRNewswire/ -- Catapult Therapeutics, a biopharmaceutical company developing novel cancer treatments, today announced the U.S. Food and Drug Administration...
United States Dana Farber Cancer Institute Drug Administration Investigational New Drug Catapult Therapeutics Wim Mol

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

Press release content from PR Newswire. The AP news staff was not involved in its creation. Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA January 27, 2021 GMT INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service p...
Inch On Gwangyoksi South Korea Claire Kim Samsung Biologics Soo Young Choi Prnewswire Samsung Biologics
Source: apnews.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science